[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tufts Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":587},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,39,75,95,126,151,184,207,230,255,275,309,332,359,386,416,443,473,493,510,541,564],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100638538","oncoplastic-surgery-outcomes-database-100638538",false,"NCT07597837","Oncoplastic Surgery Outcomes Database","Understanding Long-Term Outcomes of Oncoplastic Breast Surgery","Inclusion Criteria:\n\n* Biological females \\>= 18 years old requiring oncologic breast surgery with and without reconstruction at Tufts Medicine.\n\nExclusion Criteria:\n\n* Biological females \\\u003C 18 years old","FEMALE","18 Years",{"count":19,"type":20},1500,"ESTIMATED","1 Year","OBSERVATIONAL","This is a retrospective and prospective chart review of surgical outcomes and collecting patient satisfaction outcomes using validated surveys for oncoplastic breast surgery and Goldilocks mastectomy.",[25],"Breast Cancer","RECRUITING","2026-05-22",{"date":29,"type":30},"2026-05-27","ACTUAL",{"date":32,"type":30},"2026-02-26",{"date":34,"type":20},"2045-01",{"name":36,"class":37},"Tufts Medical Center","OTHER",2,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100590568","music-use-in-parturients-admitted-to-labor--delivery-100590568","NCT06969105","Music Use in Parturients Admitted to Labor & Delivery","A Randomized Controlled Trial of Music Use in Parturients Admitted to Labor & Delivery","Inclusion Criteria:\n\n* Age: 18 years or older\n* Laboring parturients or those scheduled for an induction of labor\n* Able to provide informed consent\n* American Society of Anesthesiologists (ASA) physical status rating of II-III\n\nExclusion Criteria:\n\n* Patient refusal\n* Impaired hearing\n* Patient is taking at least one anxiolytic medication daily at baseline\n* Intrauterine fetal demise\n* Severe psychiatric disorder",true,{"count":48,"type":20},106,"INTERVENTIONAL",[51],"NA","The goal of this clinical trial is to learn if music use affects anxiety or pain levels in parturients admitted to labor and delivery. It will also learn about the effect of music use on patient satisfaction. The main questions it aims to answer are:\n\nDoes music use affect anxiety levels in parturients admitted to labor and delivery? Does music use affect pain levels in parturients admitted to labor and delivery? Does music use affect patient satisfaction in parturients admitted to labor and delivery?\n\nResearchers will compare music to a control (no music) to see if music affects anxiety levels in parturients admitted to labor and delivery.\n\nParticipants will:\n\nListen to music or listen to no music for a 10 minute duration in the labor and delivery unit.\n\nAnswer questions about anxiety and pain levels at a few different timepoints. Have information collected from medical charts (vital signs and cervical dilation).\n\nRate their satisfaction with care.",[54,55,56],"Anxiety","Pain","Patient Satisfaction",[58,59,60,61,62,63,64,65],"music","labor and delivery","parturients","anxiety","analgesia","anesthesia","pain","epidural","2026-04-30",{"date":68,"type":30},"2026-05-01",{"date":70,"type":30},"2025-05-30",{"date":72,"type":20},"2027-05",{"name":36,"class":37},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":74},"100517359","application-of-the-personalized-n-of-1-trial-design-in-patients-with-rheumatoid-arthritis-100517359","NCT06016517","Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","In order to be eligible to participate in this study, a subject must meet all the following criteria:\n\n* Newly diagnosed adult-onset Rheumatoid Arthritis (RA) as defined by the American College of Rheumatology\u002F European League Against Rheumatism (ACR\u002FEULAR) 2021 Criteria for the Classification of RA\n* Moderately to severely active RA defined as the presence of at least 6\u002F68 tender joints and at least 6\u002F66 swollen joints\n* C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥ 1 time the upper limit of normal\n* First-line therapy with MTX for at least the 12 weeks prior to study entry with a continuous, non-changing dose for at least 8 weeks prior to study entry but continue to exhibit active RA\n* Had to discontinue MTX due to intolerability or toxicity, irrespective of treatment duration\n* Have never received etanercept, adalimumab, upadacitinib, or tocilizumab prior to first dose of study drug.\n* Provision of informed consent in English or another language in which a validated consent form is available, or via short-form consent with the assistance of a qualified interpreter.\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* 18 years of age or older\n* Ability to take oral medication and be willing to adhere to all treatment periods\n* Patients are eligible whether their disease responded partially or inadequately to first-line MTX or if they were intolerant to first-line MTX\n* Enrollment in an insurance plan that participates in or is subscribed to this trial\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA\n* Has received intra-articular, intravenous, intramuscular corticosteroids within 28 days prior to baseline\n* Known allergic reactions to components of any of the investigative biologic agents\n* Is currently receiving corticosteroids at doses \\> (greater than) 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization\n* Has experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have New York Heart Association stage IV heart failure\n* Tuberculosis infection\n* Hepatitis B or C infection\n* History of venous thromboembolic event (deep vein thrombosis, pulmonary embolism)\n* Has a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness that, in the opinion of the investigator, could constitute a risk or could interfere with the interpretation of data\n* Has an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine of \\\u003C (less than) 40 milliliter per minute per 1.73 m\\^2 (mL\u002Fmin\u002F1.73 m\\^2)\n* Has a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 times the ULN or the most recent available total bilirubin ≥1.5 times the ULN\n* Has a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for \\\u003C5 years\n* Has been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need\u002Freceive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)\n* Has a current or recent clinically serious viral, bacterial, fungal, or parasitic infection\n* Has had symptomatic herpes zoster infection within 12 weeks prior to study entry\n* Has immunocompromising condition and, in the opinion of the investigator, are at an unacceptable risk for participating in the study and using these medications\n* Has a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)\\*\n* Has evidence of active or latent tuberculosis (TB)\n* Current hospitalization or requiring hospital admission at screening\n* Pregnant or breastfeeding\n* Of childbearing potential, unwilling to use effective birth control method (highly effective contraceptive measure (e.g., combined (estrogen and progestogen containing) hormonal contraception; intrauterine device)\n* Participation in another therapeutic clinical trial for RA\n* Lack of internet access to telehealth platform\n\nState who will determine eligibility. Note that those who are designated to determine eligibility must have appropriate training, expertise, and oversight, for example a physician PI or Co-I on a biomedical study: Eligibility will be determined by the appropriately trained and delegated physician investigator or physician Co- investigator.","ALL",{"count":83,"type":20},18,"The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are:\n\n* What are the effects of different treatments on RA symptoms and condition for each individual patient\n* What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study\n\nParticipants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life fortnightly, monthly and\u002For quarterly (either in clinic or remotely) and report their level of pain on alternate days (remotely).",[86],"Arthritis, Rheumatoid","NOT_YET_RECRUITING","2026-04-08",{"date":90,"type":30},"2026-04-13",{"date":68,"type":20},{"date":93,"type":20},"2028-12-01",{"name":36,"class":37},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":104,"conditions":105,"keywords":112,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":74},"100632914","pulmonary-embolism-and-right-to-left-shunts-100632914","NCT07519876","Pulmonary Embolism and Right-to-Left Shunts","PEaRLS","Inclusion Criteria:\n\n1. Age ≥18\n2. Acute pulmonary embolism (any grade\u002Fsize)\n3. Patient or legally authorized representative is able to provide consent to participate in the study\n\nExclusion Criteria:\n\n1. Patients who, in the opinion of the study investigators, are unable to participate in required study activities\n2. Patients unable to undergo MRI imaging",{"count":103,"type":20},256,"Every fetus has a small hole in their heart, called a foramen ovale when they are developing in the womb. For most people this hole closes shortly after birth, but it doesn't close completely in 1 out of every 4 people. This is called a \"patent\" foramen ovale, or PFO. In people with a PFO it is possible for a blood clot in a vein to enter the heart, pass through the opening, and then go into an artery - this is referred to as a paradoxical embolism which passes through a \"Right-to-Left Shunt,\" or RLS. If this occurs, the blood clot can cause a stroke. The most common RLS (more than 90%) is a PFO. Much rarer causes include other types of holes in the heart (like an atrial septal defect, or ASD), or a vascular communication in the lungs (like a pulmonary arteriovenous malformation, or AVM).\n\nWe are investigating whether people with a PE are at higher risk of stroke if they happen to have an RLS compared to PE patients who don't have an RLS. This study will simply observe and compare the differences in stroke-related outcomes between those 2 groups.\n\nParticipation in the study last roughly 90-days and includes the following activities:\n\n* The study team will review your medical records to collect general information such as your age, sex, race\u002Fethnicity, height, weight, medications, medical history, and other medical information\n* Magnetic Resonance Imaging (MRI) of your brain will be done as soon as possible following your enrollment in the study. For more information on MRI scans, please see the \"MRI scan\" section below.\n* A Transcranial Doppler (TCD) with bubble study will be performed to determine if an opening is present in your heart or lungs. TCD is performed using ultrasound. A contrast called agitated saline will be injected into your vein for this test.\n* You will be asked to return for a follow-up visit 90 days after your pulmonary embolism. At this visit, the following will occur:\n\n  1. A second MRI of your brain will be performed.\n  2. You will complete a questionnaire to evaluate whether you may have had a stroke since being discharged from the hospital\n  3. You will meet with a member of the study team who will collect information about your health status.",[106,107,108,109,110,111],"Pulmonary Embolism (PE)","Right-to-Left Shunt","Stroke","Atrial Septal Defects","Patent Foramen Ovale (PFO)","Pulmonary Arteriovenous Malformation",[113,114,107,115,116,108,109,117],"Pulmonary Embolism","PE","PFO","ASD","Patent Foramen Ovale","2026-04-02",{"date":120,"type":30},"2026-04-09",{"date":122,"type":30},"2026-01-30",{"date":124,"type":20},"2028-01",{"name":36,"class":37},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":81,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":49,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":74},"100629364","phase-1-veverimer-to-decrease-net-acid-excretion-and-bone-resorption-in-adults-with-osteopenia-100629364","NCT07473713","Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia","Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia: a Dose-finding Randomized Controlled Trial","Inclusion Criteria:\n\n1. Community dwelling adults age 50 years and older (approximately equal numbers of men and women).\n2. Men should be sterile or agree to use contraception throughout the study.\n3. Women must be postmenopausal, defined as no menses in the last 5 years (to reduce variability in change in bone resorption since menopause prompts a rapid increase in bone resorption).\n4. Osteopenia will be defined as a bone mineral density (BMD) T-score at the lumbar spine, femoral neck, or total hip lower than -1 or higher than -2.5.\n5. On a prescreening interview, candidates must report a usual diet associated with an acid load by our validated short questionnaire.\n6. Estimated glomerular filtration rate (eGFR) must be 45 ml\u002Fmin or greater.\n7. Participants must agree not to change their exercise pattern or medication use during the study.\n8. Participants must agree not to change their pattern of supplement use and not to use antacids during the study because most calcium supplements and other antacids add alkali.\n9. Participants must agree to not change their eating habits or intentionally change their weight.\n\nExclusion Criteria:\n\n1. Normal BMD T-scores at all spine and hip sites, osteoporosis based on BMD T-score of -2.5 or less\n2. Respiratory illness in last month\n3. Chronic obstructive pulmonary disease (COPD)\n4. Asthma\n5. Nausea\u002Fvomiting in last month\n6. Dysphagia\n7. Malabsorption\n8. Inflammatory bowel disease\n9. Chronic diarrhea (defined as loose bowel movements daily) or constipation (≤ 2 stools per week)\n10. Insulin-requiring diabetes or fasting plasma glucose \\>125 mg\u002Fdl\n11. Untreated thyroid disease\n12. Cirrhosis\n13. Current unstable heart disease\n14. Malignancy (except non-melanoma skin cancer) or cancer therapy in last year\n15. Alcohol use \\>2 drinks\u002Fday.\n16. Individuals who are unable to provide informed consent due to cognitive impairment.","50 Years",{"count":135,"type":20},60,[137],"PHASE1","The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are:\n\n* How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion.\n* Describe the safety of veverimer based on changes in serum bicarbonate and potassium.\n* Assess the changes in bone resorption.\n* Assess the changes in bone formation.\n* Explore the effect of veverimer on physical performance.\n\nParticipants will:\n\n* Take veverimer or placebo every day or every other day for 8 weeks\n* Visit the clinic a total of 8 times (including screening) for checkups and testing\n* Keep a medication diary tracking each day they take the study drug",[140],"Osteopenia",[140,142],"veverimer","2026-03-31",{"date":145,"type":30},"2026-04-06",{"date":147,"type":20},"2026-04-15",{"date":149,"type":20},"2028-05-01",{"name":36,"class":37},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":81,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":49,"phases":163,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":74},"100627464","phase-3-vitamin-d-and-type-2-diabetes---treat-to-target-100627464","NCT07448974","Vitamin D and Type 2 Diabetes - Treat-To-Target","Vitamin D and Type 2 Diabetes, Treat-To-Target","D2d-TTT","Inclusion Criteria:\n\n1. High-risk prediabetes (\"at high risk for type 2 diabetes\") defined by meeting the following 2 prediabetes criteria established by the American Diabetes Association (ADA) in the 2010 clinical practice guidelines:\n\n   1. Fasting plasma glucose (FPG) 100-125 mg\u002FdL, inclusive\n   2. Hemoglobin A1c (HbA1c) 5.7-6.4%, inclusive\n2. Age 30-74 years, inclusive\n3. Body Mass Index ≥ 23.0 and ≤ 35.0 kg\u002Fm2\n4. Provision of signed and dated written informed consent prior to any study procedures.\n\n   Exclusion Criteria:\n5. History of diabetes (ICD10 diabetes code E08.X through E13.X) or meeting a diabetes glycemic criterion at screening, as defined by the ADA guidelines (FPG ≥ 126 mg\u002FdL or HbA1c ≥ 6.5%).\n6. History (past 2 years) of hyperparathyroidism, symptomatic or asymptomatic (i.e., radiographic) nephrolithiasis or hypercalcemia.\n7. Any medical condition (past 2 years) that in the opinion of the site investigator may increase risk for nephrolithiasis or hypercalcemia during the trial (e.g., sarcoidosis).\n8. If older than 70 years, history (past 1 year) of a fall.\n9. Use of tanning devices within 12 weeks of the baseline visit and unwilling to stop use of tanning devices for the duration of the study.\n\n   Medications and Supplements\n10. Use (past 6 months) of hypoglycemic pharmacotherapy (oral or injectable medication approved by the FDA for type 2 diabetes) for any condition (e.g., prediabetes, diabetes, polycystic ovarian syndrome, MASLD, sleep apnea) or any other medication that may affect glycemia (e.g., hydroxychloroquine)\n11. Current use of medications approved by the FDA for weight management (e.g., incretin receptor agonists) or planned use during the study.\n12. Use of supplements containing vitamin D at total doses higher than 1000 IU\u002Fday within 8 weeks of the baseline visit and unwillingness to limit vitamin D supplementation dosage to no higher than 1000 IU\u002Fday during the study. Because supplements vary widely in vitamin D content (e.g., may include cod liver or cod liver oi), participants will bring all supplements to the site for a review by the research team.\n13. Use of supplements containing calcium at total doses higher than 600 mg\u002Fday within 1 week of the baseline visit and unwillingness to limit calcium supplementation dosage to no higher than 600 mg\u002Fday during the study.\n14. Current use of medications or conditions (e.g., untreated celiac disease) that would interfere with the absorption or metabolism of vitamin D.\n15. Use of an anticonvulsant drug started within 6 months of screening. Stable regimen of anticonvulsants is allowed.\n16. History of intolerance to vitamin D supplements, allergic to any content of the study drug or unwilling to take vitamin D supplements (e.g., someone who eats a vegan diet and would object to the cholecalciferol ingredient which is produced from cholesterol extracted from sheep wool harvested from healthy living sheep).\n\n    Other Medical History\n17. Severe symptomatic cardiovascular disease based on history (unstable angina, dyspnea on exertion, paroxysmal nocturnal dyspnea, arrhythmia, congestive heart failure NYHA class II or higher, claudication)\n18. History (past 1 year) of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft.\n19. History (past 1 year) of cerebrovascular disease (stroke, transient ischemic attack).\n20. Any type of cancer (past 5 years) except for basal cell skin cancer. Prostate cancer (for men over age 55) or well-differentiated thyroid cancer not expected to require treatment (except for suppression with thyroid hormone) over the next 3 years, are not exclusions. People with history of squamous cell cancer of the skin, which was completely excised and with no evidence of metastases, are eligible.\n21. History (past 6 months) of treatment with oral (for \\> 7 days) or intravenous glucocorticoids or disease likely to require oral or intravenous glucocorticoid therapy during the study. Inhaled glucocorticoid use is not an exclusion. Epidural or intra-articular glucocorticoid injections are not exclusions, but study visits need to be conducted at least two weeks after the injection. Persons with adrenal insufficiency treated with physiologic doses of glucocorticoids who are otherwise stable are not excluded.\n22. History (past 1 year) of substance abuse or unstable psychiatric disorder that in the opinion of the site investigator would impede competence or adherence with study procedures or hinder completion of the study or increase risk.\n23. History of bariatric surgery (e.g., Roux-en-Y gastric bypass, gastric sleeve) or planned bariatric surgery in the next 2 years.\n24. Extreme (over 18 hours) intermittent fasting diets because prolonged fasting downregulates CYP2R1 activity.\n25. A life-threatening event within 30 days of screening or currently planned major surgery.\n26. Any other active medical condition (including but not limited to liver disease, wasting illness, HIV, tuberculosis, oxygen-dependent chronic obstructive pulmonary disease, organ transplant, Cushing's syndrome) that in the opinion of the site investigators would interfere with the study objectives, impede competence or adherence with study procedures or increase risk.\n27. Uncontrolled hypertension (systolic blood pressure \\> 160 mm Hg or diastolic blood pressure \\> 100 mm Hg).\n28. Poor venous access.\n\n    Laboratory Evaluation\n29. Serum liver transaminase higher than 3 times the normal range for the clinical site's laboratory, within 18 months of screening.\n30. Anemia (hematocrit \\\u003C 32 for women, \\\u003C 36 for men), whole blood transfusion (within 18 months of screening) or chronic requirement, whole blood donation (within 3 months of screening) or other condition (hemolysis, hemoglobinopathy) rendering HbA1c results unreliable as indicator of chronic glycemia. Participants who donate platelets are not excluded.\n31. Low platelet count (\\\u003C 100,000) within 18 months of screening.\n32. Chronic kidney disease, defined as estimated glomerular filtration rate \\[GFR\\] \\\u003C 50 mL\u002Fmin per 1.73 m2 from creatinine level and GFR calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations that omit race within 18 months of screening.\n33. Hypercalcemia, defined as serum calcium concentration ≥ upper limit of normal within 18 months of screening.\n34. Hypercalciuria, defined as spot urine (morning void) calcium-creatinine ratio \\> 0.275 within 18 months of screening.\n35. Baseline serum 25(OH)D level greater than 100 ng\u002FmL.\n\n    Other\n36. Participation (within 30 days of screening) in another interventional research study, and unwillingness to refrain from participating in another intervention study during the study.\n37. Previous randomization in the study. Participants who did not qualify after screening may be screened again if the prior reason for exclusion has been addressed (e.g., high blood pressure is treated).\n38. Any other reason that in the opinion of the site investigator would interfere with the study objectives, impede adherence with study procedures or hinder completion of the study or increase risk.\n\n    Women only\n39. Pregnancy (past 1 year by report or positive pregnancy test at screening), intent to become pregnant in the next 2 years. History of gestational diabetes is not an exclusion criterion.\n40. Currently breastfeeding.\n41. Use of oral contraceptives or menopausal hormone therapy started within 3 months of baseline. .\n\n    Continuous Glucose Monitoring specific\n42. Regular use of personal CGM and unwillingness to refrain from using personal CGM for the duration of the study.\n43. Use of hydroxyurea or regular use of high doses of acetaminophen (may impact CGM).\n44. Extensive skin changes (e.g., skin breakdown, rash) making CGM sensor use problematic.\n45. Significant skin sensitivity to adhesive (making CGM sensor unfeasible).","30 Years","74 Years",{"count":162,"type":20},100,[164],"PHASE3","This study tests whether taking a weekly dose of vitamin D, with the dose adjusted to reach a target blood vitamin D level, can help control blood sugar levels in adults at high risk of developing type 2 diabetes (prediabetes).\n\nResearch suggests that vitamin D may play a role in blood sugar control. The goal of this study is to see whether adjusting the dose of vitamin D to reach a specific blood vitamin D level improves blood sugar control compared with a placebo (a look-alike pill without vitamin D).\n\nOne hundred adults aged 30 to 74 with prediabetes will take part. Participants will be randomly assigned (by chance) to receive either weekly vitamin D supplements or a placebo. Neither the participants nor the research team will know which group a participant is in during the study.\n\nParticipants in the vitamin D group will start with one specific dose. After three months, a blood test will be used to decide whether the dose should stay the same or be increased to reach the target vitamin D level. Participants in the placebo group will continue taking the placebo each week.\n\nAll participants will be followed for about 18 months. During the study, they will attend scheduled study visits, have blood tests, and wear a continuous glucose monitor, a small device that measures blood sugar levels throughout the day and night. The research team will also make periodic phone calls to check on health changes, medication use, and study participation.\n\nThe main outcome of the study is the proportion of time that the participants' blood sugar levels remains in a healthy range.",[167,168],"Prediabetes","Type 2 Diabetes (T2DM)",[170,171,172,173,174,175],"vitamin D","cholecalciferol","continuous glucose monitoring","diabetes prevention","prediabetes","type 2 diabetes","2026-03-03",{"date":178,"type":30},"2026-03-05",{"date":180,"type":20},"2026-05",{"date":182,"type":20},"2031-03",{"name":36,"class":37},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":46,"sex":81,"minAge":192,"maxAge":21,"enrollmentInfo":193,"targetDuration":4,"studyType":49,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100622624","lung-ultrasound-guided-respiratory-management-in-infants-100622624","NCT07386041","Lung Ultrasound-Guided Respiratory Management in Infants","Lung Ultrasound-Guided Respiratory Management in Infants: A Single-Center Randomized Controlled Trial","NeoLUS-RCT","Inclusion Criteria:\n\n* Infants admitted to the Tufts Medical Center NICU\n* Requiring invasive or non-invasive respiratory support\n* Requiring surfactant therapy\n* Parental or guardian informed consent obtained\n\nExclusion Criteria:\n\n* Major congenital anomalies\n* Known chromosomal abnormalities\n* Congenital diaphragmatic hernia\n* Decision for comfort care\n* Surfactant administered prior to transfer from outside hospital (only excluded for surfactant decisions)","0 Years",{"count":194,"type":20},64,[51],"This single-center randomized controlled study will compare lung ultrasound-guided respiratory management with standard clinical care in infants requiring respiratory support.\n\nThe primary outcome measure is length of NICU stay.",[198],"Neonatal Respiratory Failure","2026-01-26",{"date":201,"type":30},"2026-02-04",{"date":203,"type":20},"2026-08-01",{"date":205,"type":20},"2029-02-01",{"name":36,"class":37},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":49,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":38},"100487465","a-skeletal-muscle-recovery-intervention-with-dietary-protein-in-heart-failure-100487465","NCT05627440","A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure","ASTRID-HF","Inclusion Criteria:\n\n1. Left ventricular ejection fraction (LVEF) ≤40%, New York Heart Association (NHYA) class II to IV symptoms or N-terminal pro B-natriuretic peptide (NT-proBNP) \\>300 pg\u002FmL\n2. Age 18 years to 100 years, inclusive\n3. Receiving guideline-directed medical therapy (GDMT), unless contraindicated or not tolerated\n4. Any of the following markers of severe HF within prior 12 months: i) Inotropic therapy; ii) 1 or more HF hospitalizations; iii) LVEF ≤25%; iv) Peak oxygen consumption (VO2) \\\u003C50% predicted or ≤16 mL\u002Fkg\u002Fmin; v) 6-minute walk distance \\\u003C300 meters; vi) Unintentional weight loss \\>5% of bodyweight over the past year; vii) Moderate or severe muscle wasting on physical examination; viii) NT-proBNP ≥900 pg\u002FmL\n\nExclusion Criteria:\n\n1. Pregnancy, planning to become pregnant, or women of reproductive potential unwilling to complete pre-DXA urine pregnancy test before first DXA or randomization\n2. History of left ventricular assist device (LVAD), heart transplantation, or estimated glomerular filtration rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73 m2\n3. An identified clinical disorder associated with skeletal muscle weakness\u002Fwasting (e.g., muscular dystrophy, mitochondrial disorder, active cancer, modified Rankin score greater or equal to 4 post-stroke)\n4. Milk allergy, protein allergy, lactose intolerance, and galactosemia\n5. Weight ≥350 pounds and\u002For BMI ≥40 kg\u002Fm2\n6. Initiation of obesity-dosed GLP-1 or GIP\u002FGLP-1 agonist within 3 months prior to screening, or clinical intention to begin such an anti-obesity medication within the next 6 months.","100 Years",{"count":216,"type":20},120,[51],"Severe skeletal wasting and catabolic weight loss are highly common among patients with heart failure with reduced ejection fraction (HFrEF). This prospective randomized controlled trial will compare changes in the muscle mass in the arms and the legs (appendicular lean mass) in patients with HFrEF randomized between 3 groups of no, low- or high-dose protein supplementation. The dietary protein supplementation will be Ensure(R) products manufactured by Abbott Nutrition. The Investigators hypothesize that skeletal muscle wasting in HFrEF is promoted by neurohumoral activation of catabolic metabolism (such as GDF-15 and ActRII pathways) and can be at least partially reversed by increased dietary protein intake. It is anticipated that this study will determine whether dietary protein supplementation helps to prevent muscle wasting and will advance understanding of the GDF-15 and ActRII muscle wasting pathways.",[220,221],"Heart Failure","Muscle Atrophy","2025-11-24",{"date":224,"type":30},"2025-11-25",{"date":226,"type":30},"2023-04-24",{"date":228,"type":20},"2027-12-31",{"name":36,"class":37},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":49,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":74},"100476549","pulmonary-artery-catheter-in-cardiogenic-shock-trial-100476549","NCT05485376","Pulmonary Artery Catheter in Cardiogenic Shock Trial","The Pulmonary Artery Catheter in Cardiogenic Shock Trial","PACCS","Inclusion Criteria:\n\n1. Age ≥18 years and ≤90 years\n2. Clinical heart failure presentation and left ventricular function as follows: Either 2A or 2B must be present A. Subject has de novo acute decompensated heart failure and shock with an LVEF ≤40% OR B. Subject has acute on chronic heart failure with a documented history of a LVEF ≤40% within 6 months of admission and a current LVEF ≤40% within 24 hours of screening during the current hospitalization.\n\n   NOTE: The LVEF must be quantitatively measured as ≤ 40% by an echocardiogram within 24 hours of screening. If multiple echocardiograms have been performed within 24 hours, the most recent test must be used to qualify the patient.\n3. Cardiogenic Shock (CS) defined by a lactate level ≥ 2.1 mmol\u002FL and any 2 of the following parameters within 24 hours of screening:\n\n   1. SBP \\\u003C90 mmHg for more than 30 minutes from baseline SBP\n   2. Requires the use of at least 1 vasopressor or inotrope\n   3. Requires intra-aortic balloon pump (IABP) support\n   4. Presence of congestion on exam: JVP elevated, pulmonary edema on CXR or exam, dyspnea at rest, orthopnea, bendopnea, or worsening peripheral or abdominal swelling\n4. Initial diagnosis of CS within 24 hours of screening at the enrolling site\n5. Patient or legally authorized representative provides informed consent\n\nA HIPAA waiver for screening is requested to identify potential subjects. No recruitment materials will be given to potential subjects. No identifiable data will be retained for subjects that are determined to be ineligible\n\nExclusion Criteria:\n\n1. Primary etiology of shock other than systolic left heart failure including but not limited to: acute myocardial infarction, sepsis, hypovolemia, hemorrhage, severe anemia, primary RV failure, pulmonary embolism, or tamponade.\n2. Patient has a durable ventricular assist device or temporary mechanical circulatory support (other than IABP) or PAC prior to enrollment\n3. Actively listed for cardiac transplantation (Status 7 patients are eligible for the trial)\n4. Patient transferred from another facility with a diagnosis of cardiogenic shock\n5. Any known co-morbidity other than heart failure with anticipated survival \\\u003C 6 months\n6. Pre-enrollment labs (any of the following): International Normalized Ratio (INR) \\> 3, Platelet count \\\u003C 50k, Hemoglobin \\\u003C 7\n7. Refractory or recurrent cardiac arrest (\\>1 episode requiring defibrillation or cardiopulmonary resuscitation) within 24 hours prior to screening\n8. DNR\u002F DNI status\n9. Pregnancy, child-birth within 6 months, or lactation\n10. Active infection documented by persistent fever (Temp \\> 38.4oC within 24 hours of screening) or confirmed bacteremia\n11. Implantation of PPM or ICD within past 3 months\n12. Mechanical complication of AMI (ie VSD, papillary muscle rupture, flail mitral regurgitation, free wall rupture)\n13. Anoxic brain injury\n14. On renal replacement therapy prior to enrollment\n15. Cardiac surgery within 3 months of current admission\n16. Severe aortic, pulmonic, tricuspid stenosis or acute structural mitral regurgitation or infective endocarditis\n17. History of cardiac amyloid\n18. Congenital heart disease excluding the presence of a bicuspid aortic valve\n19. Planned cardiac surgery during admission\n20. World Health Organization (WHO) Group I, III, IV, or V pulmonary hypertension\n21. Any known contraindication to PAC placement\n22. Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device that has not reached its primary endpoint\n23. Any medical or psychiatric condition such as dementia, alcoholism, or substance abuse which may preclude informed consent or interfere with any of the study procedures, including follow-up\n24. Prior stroke with any permanent neurologic deficit or any prior intracranial hemorrhage or any prior subdural hematoma or known intracranial pathology pre-disposing to intracranial bleeding, such as an arteriovenous malformation or mass\n25. Subject has previously hospitalized for COVID-19 unless he\u002Fshe has been discharged and asymptomatic for ≥4 weeks\n26. Subject is COVID-19 PCR\u002Fantigen positive within the prior 4 weeks\n27. Subject belongs to a vulnerable population \\[defined as individuals with mental disability, persons in nursing homes, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, members of the armed forces and persons kept in detention\\]","90 Years",{"count":240,"type":20},400,[51],"The primary objective of the PACCS trial is to assess if early invasive hemodynamic assessment and ongoing management with a PAC in patients with cardiogenic shock due to acutely decompensated heart failure (AHDF-CS) is associated with lower in-hospital mortality risk compared to the current standard of care with no or delayed PAC assessment.",[244,220],"Cardiogenic Shock",[246],"Pulmonary Artery Catheter","2025-10-27",{"date":249,"type":30},"2025-10-29",{"date":251,"type":30},"2022-08-23",{"date":253,"type":20},"2026-09-01",{"name":36,"class":37},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":74},"100518786","sln-mapping-and-icg-dye-for-vulvar-cancer-100518786","NCT06035068","SLN Mapping and ICG Dye for Vulvar Cancer","Sentinel Lymph Node Mapping and Detection With Indocyanine Green and Spy-Phi Handheld Camera Technology in Early-Stage Vulvar Cancer (PILOT)","Inclusion Criteria:\n\n* 18 years of age or older\n* Patients with early-stage SCC (diameter \\\u003C4 cm) of the vulva without suspicious lymph nodes at palpation or imaging who are planned for surgery at Tufts Medical Center.\n* Patients with squamous cell carcinoma, depth of invasion \\> 1mm\n* Patients with T1 or T2 tumors (FIGO staging) \\\u003C 4 cm, not encroaching in urethra or anus with clinically negative inguinofemoral lymph nodes\n* Localization and size of the tumor are such that perilesional injection of the tracers at three or four sites is possible\n* Preoperative imaging do not show enlarged (\\\u003C1.5 cm)\u002F suspicious nodes\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Inoperable tumors and tumors with diameter \\> 4 cm\n* Patients with inguinofemoral lymph nodes that are palpable on clinical exam suspicious for metastases or with cytologically proven inguinofemoral lymph node metastases\n* Radiologically enlarged (\\>1.5 cm) inguinofemoral lymph nodes\n* Patients with multifocal tumors\n* Pregnancy",{"count":263,"type":20},10,"Doctors typically use blue dye to assist in locating and extracting lymph nodes for biopsy. However, this process can prove somewhat challenging for both patients and medical teams due to its need for extensive coordination and the assistance of a nuclear medicine team. Some studies have talked about using a different method to find these lymph nodes using a special dye called Indocyanine Green (ICG). This method involves shining a special camera on the skin. So far, no studies have directly compared the ICG method to the standard blue dye. The ICG camera could make things easier for patients and doctors, and more patients might choose to have their lymph nodes checked with this new method. The goal of our study is to see if using the ICG dye is just as good as the standard method of blue dye.",[266],"Vulva Cancer","2025-09-23",{"date":269,"type":30},"2025-09-29",{"date":271,"type":20},"2025-11-01",{"date":273,"type":20},"2026-01",{"name":36,"class":37},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":49,"phases":286,"briefSummary":287,"conditions":288,"keywords":291,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":74},"100593689","glucose-empowerment-through-monitoring-and-social-support-in-pregnancy-100593689","NCT07009704","Glucose Empowerment Through Monitoring and Social Support in Pregnancy","Real-time Continuous Glucose Monitoring and Mobile-based Social Support to Promote Glucose Management During Pregnancy","GEMS-P","Inclusion Criteria:\n\n* Pregnant (\\\u003C20w0d)\n* At least 18 years to 45 years old\n* BMI \\>25, personal history of GDM, or first-degree family member with type II diabetes\n* Comfortable conversing in English\n* Own a smartphone and willing to use the CGM app and Signal\n* Receiving prenatal care and planning to deliver at Tufts Medicine (Boston)\n* Signed the consent form\n* Currently located in the United States\n\nExclusion Criteria:\n\n* Current pregnancy a multiple gestation (e.g., twins)\n* Smoked during this current pregnancy\n* Active hepatitis or HIV infection\n* Current pregnancy have any documented fetal congenital anomalies\n* Current history of heroin, cocaine, crack, LSD, or methamphetamines\n* Current history of alcohol abuse\n* Previous gastric bypass\n* Shift work that alters the sleep\u002Fwake periods\n* Have known rheumatological or chronic inflammatory state (i.e., arthritis, inflammatory bowel disease)?\n* Chronic illnesses, including diabetes and dialysis, that require regular medication use\n* Uncontrolled hypothyroidism\n* Known culture of positive chorioamnionitis?\n* An adult who is unable to consent (e.g., cognitively impaired adults)\n* Ward of the state\n* Unable to read or write English","45 Years",{"count":285,"type":20},70,[51],"The purpose of the research is to learn whether wearing a continuous glucose monitor that shows blood glucose levels in real time on a smart phone app and participating in a group chat with other research participants will help participants keep a healthy blood glucose level during pregnancy.\n\nHigh levels of blood glucose during pregnancy can lead to health problems during and after pregnancy. It may also increase the risk for health problems for the developing baby.\n\nThe investigators think our program might be a new way to help some people maintain a healthy blood glucose level during pregnancy. When pregnant people know their blood glucose levels are high, they can do things like exercise or drink water to bring their blood glucose levels down. They can also learn what foods to eat to maintain healthy blood glucose levels, and what foods to avoid. The investigators think being in a group chat with other pregnant individuals will allow participants to support and learn from each other. Pregnant individuals should also work with their healthcare providers to manage their blood glucose levels.",[289,290],"Pregnancy, Complications","Gestational Diabetes",[292,293,294,295,296,297,172,298,299,300],"pregnancy","gestational diabetes","GDM","intervention","hyperglycemia","group chat","mobile-based","behavioral change","CGM","2025-09-16",{"date":303,"type":30},"2025-09-22",{"date":305,"type":30},"2025-07-01",{"date":307,"type":20},"2026-07",{"name":36,"class":37},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":81,"minAge":315,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":331},"100544144","screening-for-al-amyloidosis-in-smoldering-multiple-myeloma-100544144","NCT06365060","Screening for AL Amyloidosis in Smoldering Multiple Myeloma","Inclusion Criteria:\n\n* Patients 40 years of age and older\n* diagnosed with either Smoldering Multiple Myeloma or a Monoclonal Gammopathy\n* dFLC greater than 23 mg\u002FL\n* abnormal FLC ratio\n* If the patient has an eGFR less than 50 mL\u002Fmin\u002F1.73m2, the FLC ratio is inconsequential. The patient only needs to meet the age and dFLC criterion.\n\nExclusion Criteria:\n\n* Patients younger than 40 years of age are not eligible\n* Patients with a previous finding of amyloid in other biopsies will not be included\n* Adults unable to consent are not eligible, including the cognitively impaired Pregnant women, pregnant minors, minors (i.e., individuals who are not yet adults), wards of the state, non-viable neonates, neonates of uncertain viability, and prisoners are not eligible","40 Years",{"count":240,"type":20},"In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.",[319],"Smoldering Multiple Myeloma",[321,322],"SMM","AL Amyloidosis","2025-08-01",{"date":325,"type":30},"2025-08-06",{"date":327,"type":30},"2024-05-01",{"date":329,"type":20},"2029-02-27",{"name":36,"class":37},13,{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":46,"sex":81,"minAge":17,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":343,"conditions":344,"keywords":349,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":74},"100505866","ventilatory-and-perfusion-abnormalities-in-individuals-with-post-acute-sequelae-of-sars-cov-2-infection-100505866","NCT05866952","Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection","Quantitative Computed Tomography to Assess Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection","PASC VQ","Inclusion Criteria:\n\n* Age ≥ 18\n* Self-reported or documented SARS-CoV-2 infection by RT-PCR or Antigen testing \\> 3 months ago or no previous history of SARS-CoV-2 infection (control group only)\n* Normal or mild abnormalities on baseline Pulmonary Function Tests (PFTs)\n* New or worsening symptoms of chronic fatigue, dyspnea or exercise intolerance after COVID-19 with otherwise unclear etiology (PASC group only)\n\nExclusion Criteria:\n\n* SARS-CoV-2 infection by RT-PCR or Antigen testing within the last 3 months\n* Inability to provide consent or non-English speaking\n* Pregnancy\n* Any respiratory infection in last 4 weeks\n* PFT relative contraindications\n* History of major cardiovascular, pulmonary, renal, hepatic, autoimmune or neuromuscular disease including asthma, COPD, interstitial lung disease, heart failure, pulmonary arterial hypertension, or prior pulmonary embolism\n* Active malignancy undergoing treatment or history of malignancy involving the lung","99 Years",{"count":342,"type":20},40,"Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations",[345,346,347,348],"Post-Acute COVID-19","Post COVID-19 Condition","Post Viral Fatigue","Dyspnea",[350],"Ventilation Perfusion Mismatch","2025-07-16",{"date":353,"type":30},"2025-07-20",{"date":355,"type":30},"2023-06-05",{"date":357,"type":20},"2026-12-31",{"name":36,"class":37},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":81,"minAge":133,"maxAge":214,"enrollmentInfo":367,"targetDuration":4,"studyType":49,"phases":369,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":74},"100545668","remote-tai-chi-for-knee-osteoarthritis-100545668","NCT06384898","Remote Tai Chi for Knee Osteoarthritis","Remote Tai Chi for Knee Osteoarthritis: An Embedded Pragmatic Trial","TAICHIKNEE","Inclusion Criteria:\n\n* Age 50 years or older\n* Treating clinician diagnosis of knee osteoarthritis\n* Have a score of 40 (visual analog version) or greater on at least 1 of the 5 questions in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (range of 0 to 100, with higher scores indicating greater pain) at baseline.\n* Able to provide informed consent\n* If randomized to the Routine Care group, willing to abstain from Tai Chi programs until completion of the study\n* If randomized to the Tai Chi group, willing to comply with the Tai Chi program (twice-a-week remote sessions for 12 weeks)\n* Has access to a home computer or device that will allow telehealth (bidirectional audio and video) delivery of the intervention\n* Is an active patient at one of the 4 participating healthcare system\n\nExclusion Criteria:\n\n* Currently practicing Tai Chi\n* Serious medical conditions (e.g., dementia, significant neurological deficits or neurodegenerative disorder, active cancer treatment, psychosis, sensory deficits) limiting the participant's ability to participate in the Tai Chi safely, as determined by the principal investigators\n* Unable to walk without a cane or other assistive device\n* Any previous or scheduled knee replacement\n* Reports severe depression defined by a Beck Depression Inventory (BDI-II) score of 29 or more.\n* Reports suicidal ideations defined by a score on BDI-II item of 2 or 3 ('I would like to kill myself' or 'I would kill myself if I had the chance').\n* Not English speaking\n* Enrollment in any other clinical trial within the last 30 days",{"count":368,"type":20},480,[51],"The goal of this pragmatic randomized trial is to evaluate the effectiveness of remote Tai Chi to treat knee pain in adults with knee osteoarthritis. The main questions the trial aims to answer are:\n\n* Compared to routine care, will patients with Knee OA receiving remote Tai Chi exhibit greater improvement in knee-related pain (WOMAC pain score, primary outcome), pain interference (PROMIS-Pain Interference, secondary outcome), and health-related quality of life at 3 months?\n* Does remote tai chi decreases healthcare utilization and analgesic use over the one-year study period?\n\nResearchers will compare remote Tai Chi added to routine care to routine care alone to see if remote tai chi works to treat knee osteoarthritis pain. Participants will participate in remotely delivered web-based tai chi sessions, twice a week for 12 weeks, or will continue to receive routine care. Participants will be followed for 12 months after randomization.",[372],"Knee Osteoarthritis",[374,375,376,377,372],"Pragmatic Clinical Trial","Implementation Science","Mind-body Therapies","Tai Chi","2025-07-02",{"date":380,"type":30},"2025-07-08",{"date":382,"type":30},"2025-04-07",{"date":384,"type":20},"2028-08-31",{"name":36,"class":37},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":46,"sex":16,"minAge":393,"maxAge":133,"enrollmentInfo":394,"targetDuration":4,"studyType":49,"phases":395,"briefSummary":396,"conditions":397,"keywords":402,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":74},"100534548","tens-unit-for-analgesia-during-iud-insertion-100534548","NCT06240260","TENS Unit for Analgesia During IUD Insertion","Utilization of Transcutaneous Electrical Nerve Stimulation (TENS) Unit for Analgesia During IUD Insertion: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Persons with a uterus desiring insertion of intrauterine device\n2. Able to provide informed consent\u002Fassent\n3. Age 12-50 years old\n4. Minors 12 years of age and older will be included in the study if postmenarchal\n\nExclusion Criteria:\n\n1. Unable to provide informed consent\u002Fassent\n2. Prior cervical procedure (ie loop electrosurgical excision procedure, LEEP)\n3. Concurrent cervical or intrauterine procedure (ie colposcopy or dilation and curettage)\n4. Cutaneous damage at the TENS electrode sites\n5. Chronic or pre-procedure use of opioids\n6. Chronic pain diagnosis\n7. Prior IUD insertion\n8. Any contraindication to intrauterine device (IUD):\n\n   1. Pregnancy\n   2. Uterine anomaly that distorts the uterine cavity\n   3. Acute pelvic inflammatory disease (PID)\n   4. Postpartum endometritis or infected abortion in the past 3 months\n   5. Unexplained abnormal uterine bleeding\n   6. Wilson's disease or copper allergy (contraindication to copper IUD only)\n   7. Breast cancer (contraindication to levonorgestrel IUD only","12 Years",{"count":342,"type":20},[51],"Subjects will be screened over the phone or in Tufts GYN clinic for participation in the study. If eligible and interested in participating, written informed consent (and assent if applicable) will be obtained. After informed consent\u002Fassent, the patient will be enrolled in the study. The patient will decide if they desire to use TENS unit during IUD insertion appointment and inform the study team. The clinic visit will proceed as normal, with additional study proceedings as follows. The study personnel will complete the 'Background Questionnaire' with the patient prior to IUD insertion. During the IUD insertion appointment, study personnel will assist in collection of the 'Study visit' data collection form. This includes recording the patient's pain score at various time points throughout the insertion procedure:\n\n* anticipated pain during IUD insertion\n* baseline pain prior to insertion\n* speculum insertion\n* tenaculum placement\n* paracervical block administration (if performed)\n* cervical dilation (if performed)\n* uterine sounding\n* IUD insertion\n* 5 minutes after IUD insertion\n\nStudy personnel will also time the insertion procedure and collect additional data as outlined in the 'Study visit data collection form.' After IUD insertion, the participant will be asked to complete the 'Post-IUD Insertion Survey.' Once this survey is complete, this will conclude the study participation. Participation will last through the study visit only.\n\nAs part of the standard of care, a urine pregnancy test will be obtained and confirmed negative prior to IUD insertion. Patients will receive routine pain management modalities per shared decision-making with their clinical provider which may include NSAID administration, paracervical block, and heating pad.",[398,399,400,401],"IUD","Analgesia","Patient Preference","Pain, Acute",[403,404,405,406,407],"iud","contraception","iud placement","pain management","teen","2025-06-03",{"date":410,"type":30},"2025-06-04",{"date":412,"type":30},"2024-04-30",{"date":414,"type":20},"2025-12-31",{"name":36,"class":37},{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":4,"enrollmentInfo":423,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":425,"conditions":426,"keywords":427,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":442},"100414889","cardiogenic-shock-working-group-registry-100414889","NCT04682483","Cardiogenic Shock Working Group Registry","CSWG","Inclusion Criteria:\n\n* Patients must have cardiogenic shock.\n\nCardiogenic shock is defined by at least one of the two categories below:\n\n1. At least 2 of the following concurrently at any point during the index hospitalization:\n\n   * Cardiac Index \\\u003C 2.2\n   * PAPI \\\u003C 1.0\n   * Cardiac Power Output ≤ 0.6\n   * MAP \\\u003C 60mmHg or a \\>30mmHg drop in MAP from baseline\n   * SBP \\\u003C 90mmHg or a \\>30mmHg drop in SBP from baseline\n   * Pulse \\> 100\n2. Require at least one acute mechanical circulatory support device, vasopressor or inotrope to maintain values above the above target.\n\nPost-cardiotomy patients must meet the inclusion criteria 72 hours after their surgery to be included in this registry.",{"count":424,"type":20},5000,"The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.",[244],[244,428,429,430,431,432,433,434],"mechanical circulatory support","hemodynamics","heart failure","acute myocardial infarction","registry","critical care","clinical outcomes research",{"date":436,"type":30},"2025-06-06",{"date":438,"type":30},"2017-12-04",{"date":440,"type":20},"2026-06-01",{"name":36,"class":37},16,{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":450,"enrollmentInfo":451,"targetDuration":133,"studyType":22,"phases":4,"briefSummary":453,"conditions":454,"keywords":458,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":74},"100477480","the-kidneycare-community-access-to-research-equity-study-100477480","NCT05497518","The KidneyCARE (Community Access to Research Equity) Study","The KidneyCARE (Community Access to Research Equity) Study: A National Registry for People With All Stages of Kidney Disease (Formerly National Kidney Foundation Patient Network)","Inclusion Criteria:\n\n* Patients with any stage of CKD, including kidney transplant recipients and patients on dialysis.\n* Age 18 years and above.\n* Willing to participate in the Study and complete the informed consent form and assent form (where applicable).\n* Able to participate in this Study, which initially will be in English and then eventually expand to other languages.\n* Patients affiliated with Geisinger Health System must have given their consent to Geisinger Health System IRB to be contacted for research projects.\n\nExclusion Criteria:\n\n* Patient not diagnosed with CKD\n* Age below 18 years\n* Not willing to participate in the Study as well as unwilling to complete the informed consent form","120 Years",{"count":452,"type":20},50000,"For chronic kidney disease (CKD), there is a lack of unique and powerful platform for patient engagement, research studies and public health advocacy work. The National kidney Foundation (NKF) launched the first nationwide registry for people at all stages and types of CKD, including people on dialysis and kidney transplant recipients, called the KidneyCARE Study (kidneycarestudy.org). The KidneyCARE Study is a non-interventional research study which means participants will not have to take medications or do any additional tests to participate. They are simply asked to share some personal and health information, and their experiences with their disease through a secure portal. The Study also collaborates with health systems to obtain additional electronic health records (EHR) data. This unique combination of data collected will address the gap of individualized educational resources and will enhance clinical research, clinical care, and health policy decisions to be centered on the patient. The Study is all online and can be accessed any time of day at kidneycarestudy.org. Participation is voluntary and free.",[455,456,457],"Chronic Kidney Disease","Dialysis","Kidney Transplant",[459,456,460,461,462,463,464],"Chronic kidney disease","Kidney transplant","Patient registry","Hereditary nephropathy","Genetic kidney disease","Rare kidney disease","2025-05-07",{"date":467,"type":30},"2025-05-13",{"date":469,"type":30},"2021-02-25",{"date":471,"type":20},"2070-02-24",{"name":36,"class":37},{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":283,"enrollmentInfo":480,"targetDuration":4,"studyType":49,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":74},"100560340","myo-inositol-during-pregnancy-to-prevent-gestational-diabetes-100560340","NCT06575868","Myo-inositol During Pregnancy to Prevent Gestational Diabetes","Continuous Glucose Monitoring in Myo-inositol Supplemented Obese Pregnant Individuals: a Feasibility Pilot Randomized Control Trial","Inclusion Criteria:\n\nSingleton gestations\n\nWomen aged \\> 18 years and \\\u003C 45 years\n\nRecruited before 16 weeks gestation\n\nObese (pre-pregnancy BMI ≥ 30)\n\nReceiving prenatal care at Tufts Medical Center\n\nPlanning to give birth at Tufts Medical Center\n\nCan tolerate glucose tolerance test\n\nWilling and able to wear CGM\n\nWilling and able to sign informed consent\n\nExclusion Criteria:\n\nMultiple gestation\n\nPreexisting diabetes\n\nTaking medications that impact body weight or metabolism (eg metformin)\n\nInability to tolerate glucose tolerance test\n\nAdults unable to consent (cognitively impaired adults)\n\nWards of the state\n\nNon-viable neonates\n\nNeonates of uncertain viability",{"count":342,"type":20},[51],"Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM).\n\nThis is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.",[484],"Pregnancy Related","2025-04-24",{"date":487,"type":30},"2025-04-29",{"date":489,"type":30},"2025-03-01",{"date":491,"type":20},"2027-06-30",{"name":36,"class":37},{"id":494,"slug":495,"hasResults":11,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":214,"enrollmentInfo":499,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":509,"locationsCount":74},"100535536","changes-in-skeletal-muscle-thickness-in-patients-with-acute-heart-failure-100535536","NCT06253104","Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure","Inclusion Criteria:\n\n1. Over 18 years of age\n2. Ejection fraction \\\u003C40%\n3. Cardiogenic shock defined by clinical criteria (including any of: lactate \\>2.5 mmol\u002FL, systolic blood pressure \\\u003C90 mmHg, acute kidney or liver injury, or cardiac index \\\u003C2.1 on hemodynamic monitoring) plus the clinical requirement for at least one pressor, inotrope, or temporary mechanical circulatory support device (MCSD)\n\nExclusion Criteria:\n\n1. History of LVAD or other durable ventricular assist device\n2. An identified clinical disorder associated with skeletal muscle weakness\u002Fwasting (e.g., muscular dystrophy, mitochondrial disorder, active cancer, modified Rankin score greater or equal to 4 post-stroke\n3. Chronic enteric and parenteral nutrition support patients\n\nIntubation or prior history of heart transplantation are not exclusion criteria if the inclusion criteria are otherwise met.",{"count":135,"type":20},"This study aims to determine, via skeletal muscle ultrasound (US), the extent, timing and relationship between skeletal muscle mass loss and outcomes after orthotropic heart transplantation (OHT) and left ventricular assist device (LVAD) implantation amongst patients with cardiogenic shock. Advanced therapies such as OHT and VADs in the heart failure (HF) population may promote skeletal muscle mass and subsequent quality of life, but there is a lack of literature assessing muscle mass changes in HF patients before and after advanced therapies using US imaging. Therefore this observational study will provide further insight into the 1) changes in lean body mass during critical illness and 2) the feasibility of using bedside US to assess lean body mass in the inpatient setting.",[220,221,502,244],"Skeletal Muscle Atrophy","2025-04-18",{"date":505,"type":30},"2025-04-23",{"date":507,"type":30},"2024-02-19",{"date":357,"type":20},{"name":36,"class":37},{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":517,"enrollmentInfo":518,"targetDuration":4,"studyType":49,"phases":520,"briefSummary":522,"conditions":523,"keywords":528,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":74},"100487395","phase-4-letermovir-for-secondary-prophylaxis-in-solid-organ-transplant-recipients-100487395","NCT05626530","Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients","A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients","Inclusion Criteria:\n\n1. Adult (\\> 18 years old) solid organ transplant recipients (heart, kidney or liver patients) recovering from treated CMV disease in whom the clinician deems that the patient need secondary prophylaxis and in whom written informed consent is obtained.\n2. Patient able to participate with follow up for 6 months\n3. Not enrolled in competing clinical trials\n\nExclusion Criteria:\n\n1. Patients with creatinine clearance less than 10 ml per min at time of enrollment\n2. Hypersensitivity to letermovir or has a CMV isolate which is known to be resistant to letermovir based on prior testing\n3. On CVVH or renal dialysis at the time of enrollment\n4. Has Child Pugh Class C severe hepatic insufficiency at screening.\n5. Has both moderate hepatic insufficiency AND moderate to severe renal insufficiency at screening.\n\n   Note: Moderate hepatic insufficiency is defined as Child Pugh Class B (Appendix 8); moderate to severe renal insufficiency is defined as CrCl \\\u003C50 mL\u002Fmin, as calculated by the Cockcroft-Gault equation.\n6. Has a history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy.\n7. Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through at least 90 days following cessation of study therapy.\n8. Is expecting to donate eggs or sperm starting from the time of consent through at least 90 days following cessation of study therapy.\n9. Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or put the participant at undue risk, as judged by the investigator, such that it is not in the best interest of the participant to participate in this study.\n10. Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the 6 months) of drug or alcohol abuse or dependence.\n\n    Note: Participants with a history of marijuana use which is not deemed excessive by an investigator or does not interfere with the participant's daily function may participate in the study.\n11. Is currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5× half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing on this study. Participants previously treated with an investigational monoclonal antibody will be eligible to participate after a 150-day washout period.\n12. Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent that is not approved or is planning to participate in a study of a CMV vaccine or another unapproved CMV investigational agent during the course of this study.\n\n    \\-","75 Years",{"count":519,"type":20},25,[521],"PHASE4","This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient.\n\nThis study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.",[524,525,526,527],"Cytomegalovirus Infections","Infection in Solid Organ Transplant Recipients","Neutropenia","Antiviral Toxicity",[529,530,531,532,533],"Cytomegalovirus infection","Letermovir","Secondary prophylaxis","T cell immunity","neutropenia",{"date":535,"type":30},"2025-04-10",{"date":537,"type":30},"2023-02-02",{"date":539,"type":20},"2025-12-15",{"name":36,"class":37},{"id":542,"slug":543,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":11,"sex":81,"minAge":549,"maxAge":550,"enrollmentInfo":551,"targetDuration":4,"studyType":49,"phases":553,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":563,"locationsCount":38},"100544842","prapela-svs-incubator-pad-for-apnea-of-prematurity-100544842","NCT06374147","\"Prapela® SVS Incubator Pad for Apnea of Prematurity","\"Prapela® SVS Incubator Pad: a Cost-effective Stochastic Vibrotactile Device to Improve the Clinical Course of Infants with Apnea of Prematurity.\"","Prapela AOP","Inclusion Criteria:\n\n* 22 week 0 days-32 weeks 6 days gestational age (preterm)\n* Either sex\n* Single birth\n* At least 4 clinically documented apnea events in the previous 24 hours\n* Caffeine citrate at least 5 mg\u002Fkg\u002Fday dosing, with or without respiratory support oxygen, nasal cannula, or CPAP without and added rate or pressure support, if considered necessary by the clinical team)\n\nExclusion Criteria:\n\n* Intubation and mechanical ventilation, or non-invasive positive pressure ventilation (NIPPV) if not intubated, or pressure support breaths while on CPAP.\n* Refusal or withdrawal of consent\n* Major congenital malformations (not including patent ductus arteriosus, small hernia)\n* Known disorder of breathing other than apnea of prematurity (e.g., congenital central hypoventilation syndrome, laryngotracheomalacia)\n* Caffeine citrate dosing exceeding FDA recommended dosing in the first 24 hours, if deemed necessary by the clinical team","0 Days","3 Months",{"count":552,"type":20},140,[51],"The study proposes to complete the development of and then establish the safety, efficacy, and clinical risk\u002Fbenefit of a novel hospital incubator pad with stochastic vibrotactile stimulation (SVS) that will provide a complementary treatment and the first improvement in the clinical management of apnea of prematurity (AOP) in over 20 years. Currently, the only approved therapy for AOP is Caffeine Citrate. The SVS mattress pad can prove to be an effective, non-invasive adjunct to Caffeine Citrate for preterm infants with potential to shorten the need for respiratory support as well as overall shortened length of stay.",[556],"Apnea of Prematurity","2025-03-04",{"date":559,"type":30},"2025-03-07",{"date":561,"type":30},"2025-02-06",{"date":357,"type":20},{"name":36,"class":37},{"id":565,"slug":566,"hasResults":11,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":11,"sex":81,"minAge":571,"maxAge":517,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":74},"100415799","minority-barriers-in-anesthesia-100415799","NCT04694339","Minority Barriers in Anesthesia","Minority Barriers to Professional Advancement in Anesthesia","Inclusion Criteria:\n\n* Members of ASA, medical students, residents, attending anesthesiologists, self-identifying as minorities\n\nExclusion Criteria:\n\n* Non-ASA members","25 Years",{"count":573,"type":20},250,"The investigators aim to survey members of the ASA (medical students, residents, and attendings) who self-identify as minorities to assess if there are systemic barriers to minorities pursuing leadership positions. The investigators hypothesize that structural issues such as a lack of formalized mentoring programs play a role in reduced minority professional advancement.",[576,577,578],"Minority Barrier","Lack of Mentoring Program","Pass Over for Promotion","2025-02-25",{"date":581,"type":30},"2025-02-28",{"date":583,"type":30},"2020-12-22",{"date":585,"type":20},"2026-08-31",{"name":36,"class":37},""]